Late filing
elevated
Filing comparison
KAZIA THERAPEUTICS LTD filed its annual report late and said it expects a significant change in results
expects significant change in results 35 days past the statutory due date.
Kazia Therapeutics Limited (the “Registrant”) is unable to file with the Securities and Exchange Commission, without unreasonable effort or expense, its Annual Report on Form 20-F for the fiscal year ended June 30, 2026 (the “Annual Report”) by November 2, 2026, the prescribed due date for such filing. The Registrant has determined that it became an accelerated filer for the fiscal year ended June 30, 2026 and, commencing with the Annual Report, is subject for the first time to the requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Additional time is needed for the Registrant to complete the procedures relating to its year-end reporting process, including finalizing those…
Evidence
- Anticipates significant change
- Yes
- Days past due date
- 35
- Other periodic reports filed
- Yes
- Routine
- No
- Severity
- elevated
- Source
- Form 12b-25 (notification of late filing)
- Stated reason
- Kazia Therapeutics Limited (the “Registrant”) is unable to file with the Securities and Exchange Commission, without unreasonable effort or expense, its Annual Report on Form 20-F for the fiscal year ended June 30, 2026 (the “Annual Report”) by November 2, 2026, the prescribed due date for such filing. The Registrant has determined that it became an accelerated filer for the fiscal year ended June 30, 2026 and, commencing with the Annual Report, is subject for the first time to the requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Additional time is needed for the Registrant to complete the procedures relating to its year-end reporting process, including finalizing those…
- Why
- The company told the SEC it could not file a periodic report on time, using Form 12b-25.